Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Should Investors Take the Leisurely Approach to Owning Carnival?

By Will Ashworth, InvestorPlace Contributor

Two cruise-related ETFs have launched since May. Both own Carnival and CCL stock. Which, if any, is the better buy of the two?

5 SPACs That Barry Sternlicht Would Buy Over Clover Health

By Will Ashworth, InvestorPlace Contributor

Real estate investor Barry Sternlicht recently insinuated Clover Health is a fraud. Are any of his SPACs better than CLOV stock?

Zomedica Is Way Undervalued Here as Its Gear Is Catching On

By Will Ashworth, InvestorPlace Contributor

InvestorPlace’s Mark Hake estimates Zomedica is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy. Here’s why I agree. 

Dump Sundial Growers Stock in Favor of Buying Retail Pure-Play Nova Cannabis

By Will Ashworth, InvestorPlace Contributor

Sundial Growers expects its acquisition of Inner Spirit to close in third quarter. Is SNDL stock the best Canadian cannabis retail option?

Hyliion Remains a Buy for Patient Investors

By Will Ashworth, InvestorPlace Contributor

As Hyliion gets ready to join the Russell 2000, HYLN stock has been on a nice run over the past month. Can the good times last?

Load More